Huisheng Biotech (300871.SZ) announced first-half results, with net profit of 206 million yuan to mother, an increase of 75.59% over the previous year

According to the Zhitong Finance App, Huisheng Biotech (300871.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 865 million yuan, an increase of 5.20% over the previous year. Achieved net profit of 206 million yuan attributable to shareholders of listed companies, an increase of 75.59% over the previous year. Achieved net profit of 142 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 43.26% over the previous year. Basic earnings per share were $1.0169.

In the first half of the year, the downstream farming industry was sluggish, pig breeding companies generally lost money, and demand for veterinary drug formulations and APIs was suppressed. During the reporting period, the company's sales revenue for chemical preparations decreased by 2.28% compared to the same period last year, and sales revenue for veterinary APIs increased 13.56% over the same period last year. Overseas sales continued to grow rapidly, with a year-on-year increase of 72.79%. Cost reduction and efficiency continued to advance, and the technical improvement project for green equipment for veterinary APIs was successfully put into operation. Due to the combined impact of cost optimization and product price increases, the gross margin of the veterinary APIs business increased by 14.91% over the same period last year. The company continued to increase investment in R&D and innovation, and R&D expenses increased 70.54% year-on-year.